Effect of intraoperative methylene blue on postoperative delirium in elderly patients undergoing joint replacement: a randomized controlled trial

What Was Tested

The paper reports a study of Methylene blue (non-peptide stack partner), published as a randomized controlled trial.

Postoperative delirium (POD) is one of the most prevalent postoperative complications after joint replacement surgery that has great impact on patients' outcomes.

Who Took Part

The study group was 217 patients.

PubMed indexes the participants as older adults and people over 80, both men and women.

In total, 217 elderly patients undergoing joint replacement surgery were randomly assigned to the MB group ( n = 109) or the control group ( n = 108).

How the Study Was Run

The design is described as randomized.

The patients were allocated by chance, so the Methylene blue (non-peptide stack partner) group and the comparison group should start out alike.

The rate of POD in both groups, 5 days following surgery, was the primary endpoint.

The secondary outcomes were delirium characteristics, postoperative pain score, telephone interview for cognitive status-modified score 1 month after surgery, and the type and incidence of adverse events (AEs).

What Was Measured

Postoperative delirium (POD) is one of the most prevalent postoperative complications after joint replacement surgery that has great impact on patients' outcomes.

Topics PubMed links to this paper include Methylene Blue, Delirium, Postoperative Complications, Incidence, Arthroplasty, Replacement and Intraoperative Care.

The authors tagged it with the keywords elderly, joint replacement and postoperative delirium.

What This Means in Plain Language

The paper is a randomized study of Methylene blue (non-peptide stack partner) in 217 patients.

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2025 (International journal of surgery (London, England)), a journal based in United States.

More context: the Methylene blue (non-peptide stack partner) compound page, all human trials.